

1 **ONLINE SUPPLEMENTAL INFORMATION**

2
3 **p38 MITOGEN-ACTIVATED PROTEIN KINASE REGULATES CHAMBER**
4 **SPECIFIC PERINATAL GROWTH IN HEART**

5 Tomohiro Yokota¹, Jin Li¹, Jijun Huang¹, Zhaojun Xiong^{1,7}, Qing Zhang², Tracey
6 Chan², Yichen Ding^{3,4}, Christoph Rau¹, Kevin Sung³, Shuxun Ren¹, Rajan Kulkarni^{3,5},
7 Tzung Hsiai^{3,4}, Xinshu Xiao², Marlin Touma⁸, Susumu Minamisawa⁶ and Yibin Wang¹,
8

9 *

- 9 1) Departments of Anesthesiology, Physiology and Medicine, Cardiovascular Research
10 Laboratories, David Geffen School of Medicine, University of California, at Los
11 Angeles Los Angeles, CA 90095, USA
12 2) Integrative Biology and Physiology, David Geffen School of Medicine, University
13 of California at Los Angeles, Los Angeles, CA, USA.
14 3) Department of Bioengineering, School of Engineering and Applied Sciences,
15 University of California, Los Angeles, CA 90095, USA
16 4) Division of Cardiology, Department of Medicine, David Geffen School of Medicine
17 at UCLA, Los Angeles, CA 90095, USA
18 5) Division of Dermatology, Department of Medicine, David Geffen School of
19 Medicine at UCLA, Los Angeles, CA 90095, USA
20 6) Department of Cell Physiology, Jikei University, Tokyo, Japan.
21 7) Department of Cardiology, The 3rd Affiliated Hospital of Sun Yat-sen University,
22 Guangzhou, China
23 8) Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles,
24 CA 90095.
25
26
27

1 **ONLINE SUPPLEMENTAL FIGURES**

2 **FIGURE LEGEND:**

3 **Figure S1. RV-specific abnormality in the cardiac-specific p38 α/β MAP kinases**

4 **knockout mouse heart. (A)** Representative genomic DNA PCR showing the floxed

5 alleles of *mapk14* (p38 α) and *mapk11* (p38 β). **(B)** Representative immunoblot of p38

6 protein in the ventricular tissues from the Control and p38cdKO heart. **(C)**. H&E stained

7 histological images of one-month old control and p38cdKO ventricles. **(D-E)**

8 Representative images of Masson trichrome stained tissue sections from the P7 **(D)** and

9 the one-month old **(E)** Control and p38cdKO hearts. **(F)** Schematic illustration of the

10 direction of M-mode echocardiogram conducted in this study to obtain the RV parameters

11 as well as LV parameters. RVW, right ventricle wall thickness, RVID, right ventricle inner

12 diameter, LVW, left ventricle wall thickness, LVID, left ventricle inner diameter. **(G)**.

13 Representative 2-D echocardiogram of image from 1-month old Control and p38-cdKO

14 mice.

15

1 **Figure S2. YAP and GSK3 signaling pathways in the p38cdKO RV. (A-C)**

2 Representative immunoblot (A) and quantification for YAP (B) and Gsk3 β (C) in P3 RV

3 tissue from the Control and the p38cdKO hearts as indicated. (n=3, mean \pm SEM) (D)

4 Representative immunohistochemical staining of Wee1 and Tropomyosin (TPM) in the

5 left (LV) and the right (RV) ventricle of the P7 Control and p38-cdKO hearts.

6

7 **Figure S3. Immunohistochemistry of myocyte apoptotic and hypertrophy in**

8 **neonatal hearts. (A-B)** Representative images of TUNEL staining in the LV (A) and

9 the RV (B) from P3 mice. (C-F) Representative images of WGA staining of the Control

10 or the p38 cdKO RV from P1 (C, E) and 1 month (D, F) old age. (G-N) Representative

11 images of WGA staining in the control or the p38 cdKO LV at E19.5 (G, K), P1 (H, L),

12 P3 (I, M), and 1 month (J, N) of age. Scale bar indicates 40 μ m.

13

14 **Figure S4, Gene expression profile in LV. (A-B)** GO classification of up-regulated

15 genes in LV of p38cdKO heart at P1 (A) and P3 (B). (C-D) GO classification of down-

16 regulated genes LV of p38cdKO heart at P1 (C) and P3 (D) stages. (E) Heatmaps from

1 all differentially express genes between p38cdKO and Control in each ventricle at P1.
2 (F) Reduced Dusp26 expression by siDusp26 mediated silencing in NRVM, (n=3, mean
3 \pm SEM).). For all panels, p value (vs. siNC, Control vs. cdKO) ** $p < 0.01$, * $p < 0.05$. (LV
4 vs. RV) # $p < 0.05$.

5

6 **Figure S5. Wg-rVista analysis on differentially expressed genes in P1 and P3 LV.**

7 Top bracket includes transcription factors over-represented for all upregulated genes and
8 bottom bracket includes transcription factors over-represented for all down-regulated
9 genes.

10

11 **Figure S6. Expression of ER stress markers. (A) RV and (B) LV expression ATF6,**
12 **Bip, Grp94, and CHOP in P3 mouse hearts. (C) Levels of cytosolic sXbp1 mRNA in LV**
13 **vs. RV. P value (control vs. cdKO) * $p < 0.05$. (n=3, mean \pm SEM). (D). Effect of IRE1 α**
14 **expression on cardiomyocyte proliferation based on Ki67 and Aurora B mRNA, ***
15 **$p < 0.05$. (n=3, mean \pm SEM). (E) Effect of Xbp1 gene silencing and p38 inhibition on**
16 **uXbp1 expression in NRVM. *** $p < 0.001$. (n=3, mean \pm SEM). (F) Effect of Xbp1**

1 gene silencing and p38 inhibition on cardiomyocyte proliferation based on Ki67 and
2 Aurora B mRNA, * $p < 0.05$. (n=3, mean \pm SEM). (G) Cell-cycle regulatory genes as
3 candidate downstream targets of Xbp1 and differentially expressed in the p38cdKO RV
4 at P3. p value and FC are calculated from RNAseq results. (H) Cell surface area of
5 NRVMs treated with p38 inhibitor or IRE1 α overexpression. (3 independent
6 experiments.) (I) Cell surface area of NRVMs transfected with siXbp1 or control. (3
7 independent experiments.)
8

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

SUPPLEMENTAL TABLES

- Table S1. Survival of p38 cdKO mouse.**
- Table S2. List of differentially expressed genes in P1 p38cdKO RV vs. Control**
- Table S3. List of differentially expressed genes in P3 p38cdKO RV vs. Control**
- Table S4. List of differentially expressed genes in P1 p38cdKO LV vs. Control**
- Table S5. List of differentially expressed genes in P3 p38cdKO LV vs. Control.**
- Table S6. List of differentially expressed genes between RV and LV in P3 Control mice.**
- Table S7. Primer sequences used for qRT-PCR.**
- Table S8. List of antibodies and their sources used in this study.**

SUPPLEMENTAL MOVIE FILES

- Supplemental Movie 1, 2. Representative images of 3D reconstruction of P3 Control heart recorded by light-sheet microscopy.**
- Supplemental Movie 3, 4. Representative images of 3D reconstruction of P3 p38cdKO heart recorded by light-sheet microscopy.**

1 SUPPLEMENTAL EXPERIMENTAL PROCEDURES

2 **Cells**

3 Neonatal rat ventricular myocytes (NRVM) were prepared from 2 day old Sprague
4 Dawley rat by enzymatic digestion with collagenase (Worthington) and pancreatin
5 (Sigma) in 1xADS buffer at 37°C as described previously ¹. NRVM were cultured in
6 serum-free DMEM supplemented with 100U/mL Pen/Strep (Invitrogen) and 1% ITS
7 (w/v) (BD Biosciences).

8 **Masson-Trichrome Staining**

9 Heart histology slides were rehydrated and stained using masson-trichrome staining kit
10 (Sigma-Aldrich) in accordance with the manufacturer's instructions. Fibrosis was
11 visualized under microscope under bright field.

12 **Immunohistochemistry**

13 Dissected mouse hearts were fixed in 10% paraformaldehyde (PFA) and embed
14 in paraffin. These hearts were sectioned in 5µm-thickness. The following antibodies were
15 used for staining at indicated dilutions; anti-tropomyosin (1:200) (T9283, Sigma
16 Aldrich); ki67 (1:200) (ab15580, Abcam); phospho-Histone H3 (Ser10) (06-570,

1 Millipore). Nuclei were stained with Hoechst 33342 (H3570, Life technologies).
2 Secondary antibodies were obtained from Life Technologies. TUNEL staining were
3 conducted using In situ Cell Death Detection Kit (Roche) in accordance with the
4 manufacturer's instructions. WGA staining was conducted using Alexa Fluor 594
5 conjugated WGA reagent (1:200) (Life technologies) in accordance with the
6 manufacturer's instructions.

7 For pH3/TPM, TUNEL/TPM, and WGA staining, 2-4images (depends on the
8 wall size) were taken to cover the most of ventricular free wall with x20 magnification
9 for analyzing. pH3 or TUNEL positive myocyte nuclei and myocyte nuclei were counted
10 using Nikon software. For WGA staining, cross-sectional area was analyzed using Nikon
11 software. To calculate total number of myocyte nuclei in whole LV or RV free-wall,
12 number of myocyte nuclei per area and total area of each ventricle free-wall were
13 measured.

14

15 **RNA and protein extraction**

16 Dissected hearts were separated in four chambers. Only free-wall of the RV and

1 LV were used for RNA or protein extraction. Total RNA was extracted from tissue or
2 cultured NRVMs using TRIzol reagent (Life technologies) in accordance with the
3 manufacturer's instructions. Nuclear and cytoplasmic RNA were extracted using
4 Cytoplasmic & Nuclear RNA Purification Kit (Noren Biotek) in accordance with the
5 manufacturer's instructions.

6 **Real-time PCR**

7 1µg RNA was used for first-strand cDNA synthesis using Random Primer
8 (Invitrogen) and SuperScriptII Reverse Transcriptase (Invitrogen) in accordance with the
9 manufacturer's instruction. Real-time PCR was performed using IQ SYBR Green
10 Supermix (Bio-Rad) with CFX-96 Real-time PCR Detection System (Bio-Rad) as
11 previously described ². Primer sequence are listed in **Table S7**.

12 **Semi-quantitative PCR**

13 cDNA from cell lysate were used for PCR reaction. PCR reaction was performed
14 using 2x Taq PCR Premix (Bioland Scientific LLC). Primers are listed in Table S7. PCR
15 products were loaded onto 4-5% agarose gel containing GelRed Nucleic Acid Gell Stain
16 (Biotiun). Images of the gel was acquired with a high resolution CCD camera (ChemiDoc

1 XRS⁺ Bio-Rad) and quantification of the bands was performed by Image Lab (Bio-Rad).

2 **RNAseq data analysis**

3 A total of 1µg RNA per sample was processed via poly-A selection and
4 fragmentation. The first-strand cDNA was generated using random primer based reverse
5 transcription and subsequently used for generating second-strand cDNA using RNase H
6 and DNA polymerase. Sequence adapters were ligated using the Illumina Paired-End
7 sample prep kit. Fragments of ~200bp were isolated by gel electrophoresis, amplified by
8 15 cycles of PCR and sequenced on the Illumina Genome Analyzer II in the paired-end
9 sequencing protocol as described³. RNA-sequencing Raw reads were trimmed for
10 adapters and analyzed using FASTQC, read fragments with quality <28 were removed.
11 Samples were then mapped to the mm10 genome using bowtie2 and analyzed using
12 cufflinks. Principal Component Analysis (PCA) was generated using ggbiplot on all
13 expressed genes defined as > 0.5 FPKM. Differential expression was calculated using
14 CuffDiff with standard parameters. The data was cut-offed based on Fold change>1.2
15 and p<0.05. Differentially expressed gene lists (control vs. cdKO) were identified using
16 DAVID Bioinformatics Resources 6.8 (<https://david.ncifcrf.gov>) to obtain GO

1 classification results. These differentially expressed lists were also submitted to whole-
2 Genome rVISTA (<http://genome.lbl.gov/vista/index.shtml>) to determine the names and
3 the number of over-represented and conserved transcriptional factor binding sites in 5000
4 bp upstream of the differentially-expressed genes.

5 **Immunoblot**

6 The concentrations of protein lysates were measured using BCA protein assay
7 reagent (Thermo Scientific) in accordance with the manufacturer's instructions. 50 µg of
8 total proteins were used for sample preparation. Targeted proteins were detected as
9 previously described ¹. Antibodies against phosphor-p38, p38, phosphor-JNK, JNK,
10 phosphor-ERK1/2, ERK1/2, phosphor-Histone H3, Histone H3, phosphor-Akt, Akt,
11 Gsk3b, cleaved Caspase3, PCNA, BIRC5, p21 were purchased from Cell Signaling.
12 Antibodies against CyclinD1, Bax, Bcl2, phosphor-Bad, Bad, Actin, GAPDH were
13 purchased from Santa Cruz. Antibodies against phosphor-Rb, Rb, Wee1, Cdk1 were
14 purchased from Abcam. Antibody against Bcl2l11 was purchased from Sigma Aldrich.
15 The antibodies and their usage were listed in Supplemental **Table S8**. Images of the gel
16 was acquired with a high-resolution CCD camera (ChemiDoc XRS⁺ Bio-Rad) and

1 quantification of the bands was performed by Image Lab (Bio-Rad).

2 **Embryo Clarity Method**

3 The mouse hearts were infused with acrylamide monomer solution overnight at
4 4 degrees C. Acrylamide monomer solution was formulated with 4% acrylamide (Bio-
5 Rad) and 0.5% w/v of the photoinitiator 2,2'-Azobis[2-(2-imidazolin-2-
6 yl)propane]dihydrochloride (VA-044, Wako Chemicals USA), in a 1x phosphate buffered
7 saline (PBS) solution. The heart samples were subsequently incubated at 37 degrees C
8 for 2-3 hours to initiate polymerization of the acrylamide into a polyacrylamide gel matrix.
9 Afterwards, the samples were rinsed in 1x PBS and placed in a clearing solution that
10 consisted of 8% w/v sodium dodecyl sulfate (SDS, Sigma Aldrich) and 1.25% w/v boric
11 acid (Fisher) with a final solution pH of 8.4. The mouse hearts were incubated at 37
12 degrees in clearing solution for 4 weeks with periodic replacement of fresh clearing
13 solution every 36 hours. Once the samples were cleared, the tissues were rinsed over 24
14 hours with 1x PBS to remove residual SDS solution. To prepare the samples for imaging,
15 the cleared mouse hearts were incubated with refractive index matching solution (RIMS)
16 at room temperature for 24 hours. To make RIMS, we dissolved 40 grams of Histodenz

1 (Sigma) in 30 mL of 0.02M Phosphate buffer (Sigma). 0.05% w/v of sodium azide
2 (Sigma) was added as a preservative for the RIMS solution. The RIMS solution was then
3 sterile filtered and stored at room temperature until use.

4 **Light-sheet microscopic imaging**

5 Light sheet imaging was carried out on a home-made system. A diode-pumped
6 solid-state laser (LMM-GB1, Laserglow Technologies, Toronto, Canada) was used as the
7 532 nm illumination source. The initial diameter of laser beam was 2 mm, and then light
8 passed through a 5x achromatic beam expander (GBE05-A, Thorlabs Inc, New Jersey,
9 USA). A beam splitter (BS013, Thorlabs Inc, New Jersey, USA) was employed to form
10 dual-illumination onto the sample from opposite directions. Each beam was focused by a
11 plano-convex cylindrical lens ($f=50$ mm, LJ1695RM-A, Thorlabs Inc, New Jersey, USA)
12 and was then reshaped by a group of achromatic doublets (AC254-060-A, AC254-100-A,
13 Thorlabs, New Jersey, USA). After passing through an $f=150$ mm lens, the beam
14 expanded to a sheet with the width of 40 mm, as well as the waist of 17 μm . The detection
15 module was installed perpendicular to the illumination plane, and it was composed of a
16 stereo microscope (MVX10, Olympus, Japan) with a 1x magnification objective








1 (Numerical aperture, NA: 0.25), a scientific CMOS (ORCA-Flash4.0LT, Hamamatsu,
2 Japan) and optical filters (Semrock, New York, USA). The sample with RIMS and 1%
3 agarose solution was embedded in a Borosilicate glass tubing whose inner diameter was
4 less than 6 mm, and then the mounted sample was held to be oriented and moved by a
5 motorized translational stage. Both the sample and its holder except for the translational
6 stage were immersed in a transparent chamber which was full of 99.5% glycerol to match
7 the refractive index among different materials. Illumination and detection are controlled
8 by a computer with dedicated SSD RAID 0 storage for fast data streaming.


9



10 **REFERENCES IN SUPPLEMENTAL MATERIAL**

- 11 1. Ota A, Zhang J, Ping P, Han J and Wang Y. Specific regulation of noncanonical
12 p38alpha activation by Hsp90-Cdc37 chaperone complex in cardiomyocyte. *Circ Res.*
13 2010;106:1404-12.
- 14 2. Gao C, Ren S, Lee JH, Qiu J, Chapski DJ, Rau CD, Zhou Y, Abdellatif M,
15 Nakano A, Vondriska TM, Xiao X, Fu XD, Chen JN and Wang Y. RBFox1-mediated RNA
16 splicing regulates cardiac hypertrophy and heart failure. *J Clin Invest.* 2016;126:195-206.





- 1 3. Lee JH, Gao C, Peng G, Greer C, Ren S, Wang Y and Xiao X. Analysis of
- 2 transcriptome complexity through RNA sequencing in normal and failing murine hearts.
- 3 *Circ Res.* 2011;109:1332-41.
- 4









cdKO/Control up-regulated in LV at P1





E




F







A




B




C




D



E




F



G

Gene symbol	Function	P-value	FC
Fgfr2	positive regulation of cell cycle	0.000	2.04
Lif	negative regulation of meiotic nuclear division	0.000	3.19
Fam83d	cell cycle	0.000	1.65
Bre	cell cycle	0.000	1.55
Ccnb2	cell cycle	0.000	1.51
Gas2l3	cell cycle arrest	0.001	1.46
Ctdspl	negative regulation of G1/S transition of mitotic cell cycle	0.001	1.40
Cdca3	cell cycle	0.001	1.43
Cdc20	cell cycle	0.001	1.48

H



I

